Pfizer (PFE)

The business may not be as strong as its performance this year suggests.

If you like dividend stocks, here's a high yielder, a Dividend King, and a turnaround story to consider as January comes to a close.

After a years-long revenue drought, there's a light at the end of the tunnel.

As the final days of January 2026 unfold, the financial world is fixed on the steps of the U.S. Supreme Court. A landmark decision in the consolidated cases of Learning Resources, Inc. v. Trump and Trump v. V.O.S. Selections, Inc. is expected within weeks, representing the most

In a landmark shift for the biotechnology and pharmaceutical industries, the U.S. Food and Drug Administration (FDA) has officially entered what experts call the “Enforcement Era” of artificial intelligence. Following the release of the January 2026 Joint Principles in collaboration with the European Medicines Agency (EMA), the FDA has unveiled a rigorous new regulatory framework [...]

They could perhaps see sustained runs beyond this year.

Pfizer Inc. (PFE) shares are trading higher on Tuesday, as the stock benefits from a price target increase at Cantor Fitzgerald. The firm raised its target to $27 from $24, providing a catalyst for the pharmaceutical giant even as the broader Healthcare sector declined 1.6% during the session.

Aclaris Therapeutics reported early study results showing its ATI-2138 drug drove rapid and lasting hair regrowth, outperforming Pfizer's Litfulo in a severe hair loss mouse model.

Eli Lilly is the leader in GLP-1 weight loss drugs today, but that advantage won't last forever.

Pfizer has lagged the broader market over the past year, and analysts remain cautious about its future outlook.

As of January 26, 2026, Merck & Co. (NYSE: MRK) stands at the most critical juncture in its 135-year history. Known globally for its dominant oncology franchise and robust vaccine portfolio, the company is currently navigating the "Keytruda Cliff"—the 2028 expiration of patents for its $30 billion-a-year blockbuster. While Merck has spent the last five [...]

The biotechnology sector has always been a high-stakes arena where clinical success can create multi-billion-dollar empires overnight, and a failed negotiation can erase a fifth of a company’s market value in a single trading session. This volatility was on full display in late January 2026 as Revolution Medicines (Nasdaq: RVMD) experienced a dramatic 20% stock [...]

Both could reward patient investors down the line.

Explore how portfolio breadth and risk profiles set these two leading bond ETFs apart for income-focused investors.

Pfizer CEO Albert Bourla criticizes RFK's vaccine stance, warns US health research is losing ground to China, and urges stronger global competitiveness.

A year after the most radical transformation of U.S. antitrust filing rules in nearly half a century, the domestic merger and acquisition (M&A) market is finally finding its rhythm. The Federal Trade Commission (FTC) and the Department of Justice (DOJ) implemented a sweeping overhaul of the Hart-Scott-Rodino (HSR)

It's a great opportunity to "buy low."

As of January 23, 2026, Johnson & Johnson (NYSE:JNJ) finds itself at a historic crossroads. After spending much of 2025 navigating the "patent cliff" of its blockbuster drug Stelara and finalizing its transition into a pure-play healthcare giant, the company has emerged with a leaner, more aggressive growth profile. Analysts

Date: January 23, 2026 Introduction In the high-stakes arena of metabolic medicine, few companies have generated as much speculative fervor and clinical awe as Viking Therapeutics (NASDAQ: VKTX). As of early 2026, the San Diego-based biotech has transitioned from a promising "dark horse" into a formidable contender challenging the global duopoly of Eli Lilly (NYSE: [...]